Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several malignancies, improving patient survival and quality of life. Endocrinopathies have emerged as a clinically significant group of immune-related adverse events (IRAEs). Although the mechanism of ICI toxicities has not been clarified, inhibition of immune checkpoints reduces immune tolerance to autoantigens, resulting in the development of autoimmunity disorders. We report current evidence regarding endocrine IRAEs that may have diagnostic and therapeutic implications. Management should be focused on a multidisciplinary approach to reach a prompt diagnosis and an appropriate and safe treatment.

Chiloiro, S., Bianchi, A., Giampietro, A., Milardi, D., De Marinis Grasso, L., Pontecorvi, A., The changing clinical spectrum of endocrine adverse events in cancer immunotherapy, <<TRENDS IN ENDOCRINOLOGY AND METABOLISM>>, 2022; (33): 87-104. [doi:10.1016/j.tem.2021.10.009] [http://hdl.handle.net/10807/200841]

The changing clinical spectrum of endocrine adverse events in cancer immunotherapy

Chiloiro, Sabrina
Primo
Writing – Original Draft Preparation
;
Bianchi, Antonio
Secondo
;
Giampietro, Antonella;Milardi, Domenico;De Marinis Grasso, Laura
Penultimo
Supervision
;
Pontecorvi, Alfredo
Ultimo
Supervision
2021

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several malignancies, improving patient survival and quality of life. Endocrinopathies have emerged as a clinically significant group of immune-related adverse events (IRAEs). Although the mechanism of ICI toxicities has not been clarified, inhibition of immune checkpoints reduces immune tolerance to autoantigens, resulting in the development of autoimmunity disorders. We report current evidence regarding endocrine IRAEs that may have diagnostic and therapeutic implications. Management should be focused on a multidisciplinary approach to reach a prompt diagnosis and an appropriate and safe treatment.
Inglese
Chiloiro, S., Bianchi, A., Giampietro, A., Milardi, D., De Marinis Grasso, L., Pontecorvi, A., The changing clinical spectrum of endocrine adverse events in cancer immunotherapy, <<TRENDS IN ENDOCRINOLOGY AND METABOLISM>>, 2022; (33): 87-104. [doi:10.1016/j.tem.2021.10.009] [http://hdl.handle.net/10807/200841]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/200841
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? ND
social impact